BN Immuno Therapeutics is developing MVA-BN-PRO, a next-generation immunotherapeutic that encodes two tumor-associated antigens, PSA and prostatic acid phosphatase (PAP), higher protection rates or prolonged survival [191, 192]. This evidence concerns the gene ACP3 and neoplasm.